US EditionInnovent Presents Updated IBI363 Data in Colorectal Cancer at ASCO 2025
- Innovent Biologics presented Phase 1 and 2 data of IBI363 for immunotherapy-pretreated melanoma at the 2025 ASCO Annual Meeting on June 1, 2025, from San Francisco and Suzhou, China.
- The data followed extensive clinical studies targeting treatment-resistant cold tumors, including acral and mucosal melanoma, which have limited efficacy with current treatments and represent a significant unmet need in China.
- In 31 heavily treated patients dosed at 1 mg/kg biweekly, IBI363 achieved a 23.3% confirmed objective response rate and a 76.7% disease control rate, with durable responses lasting a median of 14.0 months and median progression-free survival of 5.7 months.
- The median overall survival reached 14.8 months overall and 19.3 months for mucosal melanoma, while treatment-related adverse events were mostly mild, with manageable safety and only 3.2% discontinuations due to adverse effects.
- A pivotal randomized Phase 2 trial comparing IBI363 to pembrolizumab in untreated mucosal and acral melanoma started dosing in March 2025, aiming to establish IBI363 as a new immunotherapy standard for these cold tumor subtypes.
60 Articles
60 Articles
Helena Independent Record
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…
Innovent presents updated IBI363 data in colorectal cancer at ASCO 2025
SAN FRANCISCO, and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)…
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma - PressReach
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ — Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the data from Phase 1 and Phase 2 clinical studies of IBI363, first-in-class PD-1/IL-2α-bias bispecific ant…
Coverage Details
Bias Distribution
- 86% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
